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Abstract Rheumatoid arthritis (RA) is a systemic auto-
immune disease characterized by inflammation and joint
destruction that causes significant morbidity and mortality.
However, the combined use of methotrexate (MTX), a
synthetic disease-modifying anti-rheumatic drug (sDM-
ARD) and biological DMARDs (bDMARDs) has revolu-
tionized treatment of RA and clinical remission or low
disease activity (LDA) are now realistic targets, achieved
by a large proportion of RA patients. We are now in a
position to evaluate if it is possible to maintain remission or
LDA while at the same time reducing the burden of
treatment on the patient and healthcare system. Data are
emerging from large, well-conducted studies designed to
answer this question, shedding light on which patient
populations and treatment algorithms can survive treatment
discontinuation or tapering with low risk of disease flare.
For early RA, approximately half of early RA patients
could discontinue TNF-targeted bDMARDs without clini-
cal flare and functional impairment after obtaining clinical
remission by bDMARDs with MTX. In contrast, for
established RA, fewer patients sustained remission or LDA
after the discontinuation of bDMARDs and ‘‘deep remis-
sion’’ at the discontinuation was a key factor to maintain
the treatment holiday of bDMARDs. Thus, this article
provides a brief outline on withdrawing or tapering
bDMARDs once patients have achieved remission or LDA
in RA.
Key Points
The discontinuation of biological disease-modifying
anti-rheumatic drugs (bDMARDs) is possible
without clinical flare and functional impairment for
early rheumatoid arthritis (RA) patients with low
disease activity or remission.
For patients with established RA, ‘‘deep remission’’
at the time of discontinuation is required to maintain
the treatment holiday from bDMARDs.
‘‘Treatment holiday’’ from bDMARDS following
early intensive treatment may be beneficial for
reduction of drug-induced adverse effects and costs.
1 Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease, leading to synovial hypertrophy and adjacent bone
and cartilage destruction. However, the combined use of
methotrexate (MTX), a standard synthetic disease-modi-
fying anti-rheumatic drug (sDMARD) and a biological
DMARD (bDMARD) has revolutionized treatment of RA
and clinical remission or low disease activity (LDA) are
now realistic targets, achieved by a large proportion of RA
patients. Currently, discontinuation of a bDMARD without
disease flare is our next goal and desirable from the
standpoint of risk reduction and cost effectiveness, espe-
cially for patients with clinical remission or LDA. Data are
emerging from large, well-conducted studies designed to
answer this question, shedding light on which patient
populations and treatment strategies can survive treatment
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discontinuation or tapering with low risk of disease flare
[1–5]. The goal of the present Leading article is to deter-
mine if discontinuation of a bDMARD is possible in RA
patients, after obtaining LDA or clinical remission by the
use of bDMARDs. The content is based on results of a
systematic literature review as well as new information.
2 Systematic Literature Search Regarding
Discontinuation of Biological DMARDs (bDMARDs)
First of all, a search of PubMed using a search strategy that
combined terms for ‘‘rheumatoid arthritis’’, ‘‘biological
agent’’ and ‘‘discontinuation, discontinuing or cessation’’
was performed as below:
#1. rheumatoid arthritis
#2. discontinuation OR discontinuing OR stop OR stop-
ping OR cessation OR withdrawal
#3. biological dmards OR biological drugs OR anti-tnf
OR tnf inhibitor OR infliximab OR remicade OR
etanercept OR enbrel OR adalimumab OR humira
OR tocilizumab OR actemra OR roactemra OR
abatacept OR orencia OR golimumab OR simponi
OR certolizumab OR cimzia OR rituximab OR
rituxan
#4. remission OR low disease activity
#5. English[Language]
#6. arthritis, juvenile rheumatoid[MeSH]
#7. review[Filter]
#8. #1 AND #2 AND #3 AND #4 AND #5 NOT #6 NOT
#7
During screening the titles and abstracts of the citations
and retrieved relevant articles, the following selection cri-
teria were used; (a) clinical trials of bDMARDs in patients
with RA, followed by discontinuation of a bDMARD due
to preferable effectiveness but not to adverse events nor to
insufficient efficacy, (b) patients with RA [18 years old,
(c) data available on one or more of following pre-specified
outcomes: proportion of remission or low disease activity
after at least 12 weeks of discontinuation and/or proportion
of re-administration of a bDMARDs (d) published after
1998 that the first bDMARD to be available.
By performing a PubMed search on July 5th, 2014, 86
original research articles were found. Then systematic lit-
erature review revealed that 19 articles were as candidate
studies, and 67 articles were excluded. The reasons for
exclusion were categorized into three groups; (1) No
description of discontinuing biologics, (2) Reasons for
discontinuing biologics are not specified, (3) No descrip-
tion of discontinuing biologics due to preferable effec-
tiveness. We also added the abstracts search on the
American College of Rheumatology (ACR) 2011, 2012,
2013, the European League against Rheumatism (EULAR)
2012, 2013, 2014, and finally identified 26 reports as the
candidate studies, summarized in Table 1.
3 Stopping a bDMARD in Established RA
There is little information about characteristics of patients
in which a bDMARD is successfully discontinued without
functional and radiographic damage progression in patients
with long-term established RA encountered during routine
clinical practice.
3.1 RRR Study
We first reported a RRR study aimed at the possibility of
biologic-free remission in RA patients whose mean disease
duration was 5.9 years [6]. This study included a total of
114 patients, from 26 centers, with RA who reached and
maintained LDA (disease activity score 28; DAS28 \3.2)
for more than 24 weeks with infliximab treatment. Among
the 102 evaluable patients who completed the study, 56 and
44 maintained LDA and remission (DAS28 \2.6),
respectively, after 1 year and showed no changes in
radiological damage measured by yearly progression of
modified total Sharp score (mTSS) and functional distur-
bance measured by health assessment questionnaire-dis-
ability index (HAQ-DI) score. By logistic regression and a
receiver-operating characteristic curve (ROC) analysis, the
cut-off point for achieving RRR at the time of patient
enrollment was a DAS28 of 2.22, and a ‘deep’ remission
was necessary at the time of the discontinuation. The study
demonstrated that 71.4 % patients with deep remission
(DAS28 B2.22) were able to continue LDA for 1 year,
whereas only 32.6 % patients with a DAS28 score of
between 2.22 and 3.2 were able to continue LDA, sug-
gesting that established RA patients in deep remission have
a possibility to achieve biologic-free remission.
3.2 HONOR Study
We also carried HONOR study to investigate the possi-
bility of discontinuing adalimumab for 1 year without
flaring measured by DAS28-ESR C3.2 in RA patients [7,
8]. Prior to the study, 197 RA patients with inadequate
response to MTX were treated with MTX and adalimumab
and 75 patients met the adalimumab-free criteria (steroid-
free and sustained DAS28-ESR remission for more than
6 months). The mean disease duration and DAS28-ESR
score in 75 patients was 7.5 years and 5.1 at baseline,
respectively. Of the 75 patients, 52 (69 %) agreed to ada-
limumab discontinuation and 23 patients continued to use
adalimumab for 1 year. The remission rate (83 %) and the
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2134 Y. Tanaka, S. Hirata
rates of LDA (91 %) measured by DAS28-ESR in the
adalimumab continuation group were significantly higher
than those (48 and 62 %, respectively) in the adalimumab
discontinuation group 1 year after the continuation or dis-
continuation decision was made. Re-administration of
adalimumab to patients with flare was effective in returning
LDA within 6 months in 90 % and 9 months in 100 %
patients. In the analysis of predictive factors related to
sustaining remission for 1 year, only DAS28-ESR had a
marked correlation with sustained remission in multivariate
analyses. Subsequent ROC analysis for high estimation of
sustained remission indicated a cut-off value for the ada-
limumab-free remission of 1.98. In patients with DAS28-
ESR B1.98 at the discontinuation, their remission rates
were approximately 70 % at 1 year after the discontinua-
tion, indicating that ‘‘deep remission’’ would be a key for
successful discontinuation of adalimumab in established
patients with RA.
3.3 ADMIRE Study
In the ADMIRE study, 33 RA patients (median disease
duration 8 years) in stable DAS28 remission for more than
3 months with MTX plus adalimumab were randomized to
continue adalimumab or to discontinue it for 52 weeks [9].
At 28 weeks, 15 of 16 (94 %) and 5/15 (33 %) in an
adalimumab-continued group and in the discontinued
group, respectively, were in DAS28-remission. In long-
term extension of the BRIGHT study, 46 RA patients
(mean disease duration 10.3 years) whose DAS28-CRP
was less than 2.7 by MTX plus adalimumab were ran-
domized to a continued group or discontinued group. Only
4 of 22 adalimumab-discontinued patients (18.2 %) main-
tained LDA through week 52 [10].
3.4 DOSERA Study
In the DOSERA study, 73 RA patients (average of disease
duration 13.6 years) in stable LDA for more than
11 months with MTX plus etanercept were randomized to
MTX plus etanercept 50 mg/week, 25 mg/week or pla-
cebo. The percentage of non-failures at 48 weeks was
52 % for etanercept 50 mg, 44 % for etanercept 25 mg and
13 % for placebo groups [11]. In the PRESERVE study,
after patients with moderately active RA despite MTX
were treated with etanercept 50 mg/week and MTX for
26 weeks, 604 patients who achieved LDA were random-
ized to MTX plus etanercept 50 mg/week, 25 mg/week or
placebo [12]. At weeks 52 after the randomization, sus-
tained LDA was observed in 82.6 % of patients treated
with MTX plus etanercept 50 mg/week, 79.1 % of those
with MTX plus etanercept 25 mg/week and 42.6 % of
those with MTX alone.
3.5 ORION Study
In the ORION study, abatacept was discontinued in 34 RA
patients (mean disease duration 6.4 years) with a DAS28-
CRP remission on MTX plus abatacept. At 52 weeks after
the withdrawal, 58.8 % failed from DAS28-CRP remission
[14].
3.6 ACT-RAY Study
In the ACT-RAY study, 556 established RA patients (mean
disease duration 8.2 years) who inadequately responded to
MTX were randomized to either add TCZ 8 mg/kg to MTX
or to switch to TCZ 8 mg/kg with oral placebo [15]. About
50 % of patients entering into year 2 discontinued toc-
ilizumab after achieving DAS28 \2.6 at 2 consecutive
visits and 86 % of these patients experienced flare before
the end of year 2. In the DREAM study, 187 established
RA patients who showed LDA or remission by DAS28,
median disease duration was 7.8 years, preceding toc-
ilizumab monotherapy period was 4.0 years and DAS28
was 1.5, discontinued tocilizumab [16]. Only 13.4 % of
them kept LDA, but 9.1 % fulfilled drug-free remission at
52 weeks.
There results indicate that patients with established RA
in sustained remission or LDA after the discontinuation of
a bDMARD were controversial among studies or difficult
in many studies and the proportion of patients who could
successfully discontinue bDMARDs ranged from 9 to
48 % at 1 year. However, from HONOR study and RRR
study, deep remission is required to sustain remission after
the discontinuation of a bDMARD and DAS28-ESR cut-
off point at discontinuation was 1.98 achieving remission at
week 52 in the adalimumab discontinued group and 2.22
for achieving LDA at week 52 in the infliximab-free group
[6–8]. In fact in HONOR study, approximately 80 %
patients with deep remission (DAS28-ESR B1.98) were
able to sustain LDA for 1 year without adalimumab,
whereas, only 42 % patients with mild remission were able
to do so, although there was no statistically significant
difference between the two groups. Meanwhile, 60 %
patients with mild remission experienced flaring within a
year, suggesting that mild remission may be insufficient for
the discontinuation and that adalimumab should be con-
tinued in such patients even under DAS28 remission. Thus,
‘‘treatment holiday’’, successful discontinuation of a
bDMARD for a certain period, is now feasible in some
patients with long-standing RA encountered during routine
clinical practice, but ‘‘deep remission’’ at the discontinua-
tion is required to keep the treatment holiday of
bDMARDs.
In our institution, among 619 patients including both
early and established RA who were treated with infliximab
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plus MTX, 102 patients reached bDMARD-free remission
(manuscript in preparation). The baseline factors affecting
infliximab-free remission were disease duration and rheu-
matoid factor (RF), indicating that patients with early RA
have more chance to discontinue bDMARDs after obtain-
ing remission.
4 Treatment Holiday from bDMARDs in Early RA
In early RA patients several studies including TNF20,
OPTIMA, HIT HARD, IDEA, PRIZE, EMPIRE and BeSt
have been undertaken to investigate whether remission can
be sustained after a bDMARD targeting TNF is discon-
tinued after following disease control.
4.1 TNF20 Study
The study regarding bDMARD-free treatment in RA
patients was first reported by a TNF20 study [17, 18].
Patients with early RA who had less than 12 months of
symptoms were treated with a combination of infliximab
and MTX. One year after stopping induction therapy,
response was sustained in 70 % of patients who received
infliximab and MTX. A significant reduction in magnetic
resonance imaging evidence of synovitis and erosions at
1 year was also observed.
4.2 BeSt Study
The Behandelstrategiee¨n (BeSt) study was conducted to
compare 4 treatment strategies and to observe clinical
outcomes in patients with early RA (disease duration less
than 2 years after onset, mean disease duration 0.8 years)
[19–23]. In BeSt study 508 patients with high disease
activity were distributed to 4 groups and were evaluated
by DAS44 every three months. If DAS44 [2.4 (inter-
mediate or high disease activity), change or addition of
medications is required, if DAS44 B2.4 (remission or
LDA), current medication is continued, and if
DAS44 B2.4 continued over 6 months, decrease and/or
discontinue concomitant medications including infliximab.
In the fourth group who started by infliximab 90 patients
of 120 (75 %) achieved LDA and infliximab was with-
drawn in 77 cases because they maintained LDA for
6 months. The LDA was kept in 43/77 patients (56 %) for
at least 1 year. Furthermore, more than half of patients
who discontinued infliximab successfully maintained
LDA for more than 8 years, according to the 8-year fol-
low-up of infliximab-free survival in patients with early
RA.
4.3 IDEA Study
In the IDEA study, patients with DMARD-naı¨ve early RA
were randomized to MTX plus infliximab and MTX plus
intravenous steroid therapy as remission induction [24]. In
the former group, 24.5 % (14/55) had stopped infliximab
due to sustained remission (DAS44 \1.6 for 6 months) and
78.6 % (11/14) of them maintained remission for half a
year.
4.4 OPTIMA Study
A multinational, double-blinded, randomized controlled
study was performed to determine the optimal protocol for
treatment initiation with adalimumab plus MTX in patients
with RA (OPTIMA) [12]. In this study, the withdrawal of
adalimumab in early RA patients (with a mean RA duration
of 3.9 months) was also assessed. Outcomes of withdrawal
or continuation of adalimumab were assessed in patients
who achieved a stable LDA target after 26 weeks of ini-
tially assigned treatment with adalimumab and MTX. Of
the 466 RA patients treated with adalimumab and MTX,
207 (44 %) achieved the stable LDA measured by DAS28-
CRP at weeks 22 and 26 and were re-randomized to pla-
cebo plus MTX or adalimumab plus MTX during the
second study period for 52 weeks. After 52 weeks, 91 and
86 % of patients who continued adalimumab treatment
maintained LDA and remission, respectively, compared
with 81 and 66 % of patients who withdrew from ada-
limumab treatment.
4.5 HIT HARD Study
In a HIT HARD study, the withdrawal of adalimumab in
patients with early RA (mean RA duration 1.7 months) was
also assessed whether an early induction therapy with
subsequent step down strategy leads to a long-term clinical
effect in early RA patients as compared to initial and
continued MTX [25]. During the first 24 weeks, 172
patients were treated with adalimumab or placebo with
MTX; after week 24, both groups were treated with MTX
alone for 24 weeks. During the induction phase, 47 % of
patients treated with MTX and adalimumab achieved
DAS28-remission; at week 48, 44 % of these patients were
still in remission by 24 weeks of adalimumab-free
treatment.
4.6 PRIZE Study
In the PRIZE study MTX-naı¨ve early RA patients with
moderately active disease activity were treated with eta-
nercept and MTX and DAS28 remission was achieved by
70 % of patients [26]. These patients were randomized to a
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double-blinded 39-week period of reduced-dose etanercept
(25 mg) plus MTX, MTX plus subcutaneous placebo, or
oral placebo and subcutaneous placebo. At week 39 the
sustained remission was observed in 63.5 % of patients
with etanercept plus MTX, 38.5 % with MTX, those who
discontinued etanercept, and 23.1 % with placebo, those
who discontinued etanercept and MTX. There was no
significant radiographic progression in any treatment
group.
4.7 EMPIRE Study
In EMPIRE study, 110 DMARD-naı¨ve patients with early
inflammatory arthritis and the minimum of one synovitis
joint were randomized to MTX plus etanercept or MTX
plus placebo for 52 weeks [27]. Injections were stopped in
all patients at week 52 or injections were stopped early in
those with no tender or swollen joints for more than
26 weeks. In the MTX ? ETN group, 41.9 and 57.7 %
remained in remission and LDA according to DAS28,
respectively, from week 52 to week 78.
Taken together, these recent studies indicate that
30–79 % of early RA patients could discontinue bDM-
ARDs without clinical flare and functional impairment
after reduction of disease activity to LDA or remission by
bDMARDs in combination with MTX. Although there are
limited studies, a treatment holiday of bDMARDs is now
feasible in approximately half of patients with early RA.
5 De-Escalation of bDMARDs in RA
On the other hand, de-escalation (dose reduction/interval
prolongation) of bDMARDs appears to attract attention
because complete discontinuation of bDMARDs is rather
difficult for the established RA patients. A group in the
Netherland performed the first observational cohort study
regarding de-escalation of bDMARDs in RA patients with
stable LDA and reported that the down-titration of inflix-
imab was feasible for 45 % of patients, with a mean dose
reduction of 60 % after 1 year [28]. In the PRESERVE
study, patients with RA achieving remission after 1-year
treatment with etanercept were randomly assigned with
full-dose maintenance (50 mg weekly), dose reduction
(25 mg weekly) or discontinuation for 1 year [12]. How-
ever, dose reduction was associated with a non-significant
risk of relapse and structural damage progression at 1 year
as compared to full-dose maintenance. Recent interval
prolongation STRASS study, an 18-month randomized
controlled trial, was undertaken by a French group to
compare the impact of a DAS28-driven step-down strategy
to maintenance strategy [29]. Established RA patients, with
etanercept or adalimumab for longer than 1 year, DAS28
remission for more than 6 months, stable damage on
X-rays, were randomized to TNF-inhibitor injection spac-
ing arm (n = 64) and a maintenance strategy arm
(n = 73), then followed every 3 months for 18 months.
The inter-injection interval was increased every 3 months
up to full stop at 4th step. At 18 months, 47 (73.4 %)
patients of the spacing arm tapered TNF-blockers. Mean
DAS28, mean HAQ and structural damage progression
were not significantly different between arms. However,
relapse (DDAS28 [ 0.6 ? DAS28 [ 2.6) occurred at least
once more frequently in the spacing arm than in the
maintenance arm (81 vs. 56 %, p = 0.0009).
However, in these studies it is not clear how to monitor
the disease activity and retreat or increase the dose in case
of disease worsening after dose reduction, which may
rather result in equally good care as just continuing treat-
ment. Furthermore, when considering de-escalation trials,
there are quite various factors underlying to de-escalate
bDMARDs. For instance, (i) baseline characteristics; early
or established RA, with or without MTX and/or other
DMARDs, LDA or remission, remission criteria, duration
of disease control and so on, (ii) targeted medications;
bDMARDs or MTX, TNF-inhibitors or non-TNF-bDM-
ARD, dose reduction or interval prolongation, schedule of
the dose reduction, criteria for de-escalation, reduction of
all at once and many, (iii) disease flare after de-escalation;
definition of flare, how to treat flared cases, restart all or
step-up at flare and etc. Thus, there are too many factors
regarding the de-escalation, very careful consideration
regarding inclusion criteria, protocol, assessment, etc.
would be required to perform de-escalation trials in RA
patients. On the other hand, although titrating patients to
the lowest dose may save medication costs, it may also lead
to increased number of patient contacts and consequent
costs. So far, none of the previous controlled de-escalation
studies included a disease activity guided strategy or cost-
effectiveness analyses. Taken together, in this manuscript
we have shed light upon discontinuation of bDMARD
rather than de-escalation strategy.
6 Conclusion
The combination of MTX and bDMARDs targeting TNF,
IL-6 and T cells has revolutionized RA treatment, leading
to clinical, functional and structural remission. Since we
have obtained strong weapons to treat RA, a new strategy
rather than a new target should be required for the
advanced therapy of RA. For instance, how and when
bDMARDs are discontinued without disease flare is an
emerging theme to strategically treat RA. We are now in a
position to evaluate what is possible in terms of main-
taining remission or LDA while at the same time reducing
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the burden of treatment on the patient and healthcare sys-
tem. Data emerging from large, well-conducted studies
indicate that approximately half of early RA patients could
discontinue bDMARDs targeting TNF without clinical
flare and functional impairment after obtaining reduction of
disease activity to LDA or remission by bDMARDs in
combination with MTX. Saleem et al. [30] also reported
that a TNF-inhibitor-free sustained remission rate was
60 % after acquiring DAS28 remission in MTX-naı¨ve early
RA patients. Within the initial treatment group, the only
clinical predictor of the successful discontinuation was
shorter symptom duration prior to receiving therapy
(median 5.5 vs. 9.0 months, p = 0.008). No other clinical
features including activity measured by power doppler
were associated with the discontinuation of bDMARD.
However, fewer patients sustained remission or LDA
after the discontinuation of bDMARDs for patients with
established RA, compared to early RA. It is often difficult
to successfully discontinue bDMARDs and the results were
controversial among studies. The HONOR study and RRR
study indicated that ‘‘deep remission’’ is required to suc-
cessfully discontinue bDMARDs in established RA
patients; DAS28-ESR cut-off point at discontinuation was
1.98 achieving remission at week 52 in the adalimumab
withdrawal group and 2.22 for achieving LDA at week 52
in the infliximab-free group [6–8]. Thus, the mild remis-
sion is insufficient for the discontinuation and bDMARDs
should be continued in such patients even under DAS28
remission.
Thus, ‘‘treatment holiday’’ of bDMARDs is now feasi-
ble in some patients with RA with long-standing RA, but
‘‘deep remission’’ at the discontinuation is a key factor to
keep the treatment holiday of bDMARDs. However, such
intensive treatment would have the potential of reducing
drug-induced adverse effects and reducing long-terms
medical costs, although the risks of worsening clinical,
structural and functional outcomes should be considered
with careful monitoring.
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